DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here

Business Development

Our team of consultants are highly experienced in optimizing R&D, in-licensing, and acquisition strategy on behalf of our biopharmaceutical and med tech clients. For each potential asset, we thoroughly assess the opportunity across three critical factors: impact on unmet need, organizational fit, and development risk. Our in-house therapeutic expertise and commercial experience enables us to make informed, targeted, and data-driven recommendations.


Depending on the stage you are at in your assessment of an asset, we can evaluate the market potential of your product from a range of altitudes including industry macro trends, technological advances, and political, economic, and social patterns, or a deeper analysis using thorough primary research to quantify and forecast a specific opportunity.


John Lebbos DRG

John Lebbos

Partner DRG Consulting
David Eckford Consultant Decision Resources Group

David Eckford

Partner, DRG Consulting
Adrienne Lovink Partner Decision Resources Group Consulting

Adrienne Lovink

Partner DRG Consulting

Want to see more? Discover the rest of the Consulting Team here.